Paul Choi
Stock Analyst at Goldman Sachs
(4.43)
# 1,158
Out of 4,534 analysts
362
Total ratings
56%
Success rate
9.8%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Maintained: Hold | $18 → $44 | $41.12 | +7.00% | 24 | Jul 15, 2026 | |
| EWTX Edgewise Therapeutics | Rated: Hold | $20 → $32 | $38.81 | -17.55% | 3 | Jun 17, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $95 → $90 | $36.99 | +143.31% | 4 | Jun 5, 2026 | |
| RGNX REGENXBIO | Maintained: Hold | $12 → $10 | $10.32 | -3.10% | 11 | May 14, 2026 | |
| CRVS Corvus Pharmaceuticals | Maintained: Buy | $40 | $14.10 | +183.69% | 3 | May 14, 2026 | |
| ARVN Arvinas | Maintained: Sell | $6 | $8.02 | -25.19% | 8 | May 12, 2026 | |
| BBIO BridgeBio Pharma | Maintained: Buy | $112 → $116 | $80.76 | +43.64% | 35 | May 8, 2026 | |
| LNTH Lantheus Holdings | Maintained: Hold | $77 → $94 | $104.40 | -9.96% | 5 | May 7, 2026 | |
| EXEL Exelixis | Maintained: Buy | $50 | $55.53 | -9.96% | 8 | May 6, 2026 | |
| VIR Vir Biotechnology | Maintained: Buy | $21 | $9.23 | +127.52% | 25 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 → $101 | $79.11 | +27.67% | 10 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $10.65 | - | 18 | Apr 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $255 | $251.76 | +1.29% | 25 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $75 | $66.04 | +13.57% | 12 | Mar 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $12 | $13.60 | -11.76% | 27 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $8 → $0.5 | $0.141 | +254.61% | 9 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | $50 → $55 | $78.01 | -29.50% | 25 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $55 | $62.58 | -12.11% | 18 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.48 | n/a | 1 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $7.04 | n/a | 25 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.28 | n/a | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $19 | $11.32 | n/a | 19 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $59.11 | n/a | 1 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $133.29 | $17.68 | n/a | 1 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 | $5.19 | n/a | 5 | Jun 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $25 → $3.5 | $6.44 | n/a | 4 | Apr 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $7 | $8.30 | n/a | 8 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $12 → $9 | $11.50 | n/a | 5 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $15 → $17 | $101.00 | n/a | 3 | Mar 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $50 | $5.95 | n/a | 1 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Sell | n/a | $150,000.00 | n/a | 2 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $135 | $173.00 | n/a | 4 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $18 → $20 | $64.84 | n/a | 5 | Mar 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $135 → $165 | $115.65 | n/a | 2 | Nov 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $90 | $1,146.90 | n/a | 1 | Apr 7, 2017 |
UroGen Pharma
Jul 15, 2026
Maintained: Hold
Price Target: $18 → $44
Current: $41.12
Upside: +7.00%
Edgewise Therapeutics
Jun 17, 2026
Rated: Hold
Price Target: $20 → $32
Current: $38.81
Upside: -17.55%
Vera Therapeutics
Jun 5, 2026
Maintained: Buy
Price Target: $95 → $90
Current: $36.99
Upside: +143.31%
REGENXBIO
May 14, 2026
Maintained: Hold
Price Target: $12 → $10
Current: $10.32
Upside: -3.10%
Corvus Pharmaceuticals
May 14, 2026
Maintained: Buy
Price Target: $40
Current: $14.10
Upside: +183.69%
Arvinas
May 12, 2026
Maintained: Sell
Price Target: $6
Current: $8.02
Upside: -25.19%
BridgeBio Pharma
May 8, 2026
Maintained: Buy
Price Target: $112 → $116
Current: $80.76
Upside: +43.64%
Lantheus Holdings
May 7, 2026
Maintained: Hold
Price Target: $77 → $94
Current: $104.40
Upside: -9.96%
Exelixis
May 6, 2026
Maintained: Buy
Price Target: $50
Current: $55.53
Upside: -9.96%
Vir Biotechnology
May 6, 2026
Maintained: Buy
Price Target: $21
Current: $9.23
Upside: +127.52%
May 5, 2026
Reiterated: Buy
Price Target: $95 → $101
Current: $79.11
Upside: +27.67%
Apr 30, 2026
Maintained: Hold
Price Target: n/a
Current: $10.65
Upside: -
Apr 8, 2026
Maintained: Buy
Price Target: $255
Current: $251.76
Upside: +1.29%
Mar 10, 2026
Maintained: Buy
Price Target: $75
Current: $66.04
Upside: +13.57%
Feb 25, 2026
Maintained: Sell
Price Target: $12
Current: $13.60
Upside: -11.76%
Feb 24, 2026
Downgraded: Hold
Price Target: $8 → $0.5
Current: $0.141
Upside: +254.61%
Dec 3, 2025
Maintained: Sell
Price Target: $50 → $55
Current: $78.01
Upside: -29.50%
Oct 29, 2025
Maintained: Buy
Price Target: $32 → $55
Current: $62.58
Upside: -12.11%
Feb 11, 2025
Downgraded: Hold
Price Target: n/a
Current: $4.48
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $7.04
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $1.28
Upside: n/a
Jul 31, 2024
Maintained: Hold
Price Target: $19
Current: $11.32
Upside: n/a
Jun 4, 2024
Maintained: Buy
Price Target: n/a
Current: $59.11
Upside: n/a
Nov 10, 2023
Maintained: Hold
Price Target: $133.29
Current: $17.68
Upside: n/a
Jun 28, 2023
Maintained: Buy
Price Target: $19
Current: $5.19
Upside: n/a
Apr 3, 2022
Downgraded: Hold
Price Target: $25 → $3.5
Current: $6.44
Upside: n/a
Nov 5, 2021
Maintained: Hold
Price Target: $8 → $7
Current: $8.30
Upside: n/a
Sep 22, 2021
Downgraded: Hold
Price Target: $12 → $9
Current: $11.50
Upside: n/a
Mar 4, 2021
Maintained: Buy
Price Target: $15 → $17
Current: $101.00
Upside: n/a
Nov 9, 2020
Initiated Coverage: Buy
Price Target: $50
Current: $5.95
Upside: n/a
Aug 24, 2020
Maintained: Sell
Price Target: n/a
Current: $150,000.00
Upside: n/a
Jun 29, 2020
Downgraded: Hold
Price Target: $135
Current: $173.00
Upside: n/a
Mar 30, 2020
Upgraded: Hold
Price Target: $18 → $20
Current: $64.84
Upside: n/a
Nov 1, 2017
Maintained: Buy
Price Target: $135 → $165
Current: $115.65
Upside: n/a
Apr 7, 2017
Reiterated: Buy
Price Target: $90
Current: $1,146.90
Upside: n/a